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serum albumin was 3.5 g/dL and his nutrition was well main-
tained. His weight increased to 85 kg.
Twelve months later, the patient became anuric. His Kt/V
fell to 1.7/week and the CrCl to 47 L/week. The Dialysis Out-
comes Quality Initiative (DOQI) targets for APD are a Kt/V
of 2.1/week and a CrCl of 63 L/week. Accordingly, his physician
altered the prescription. Dwell volumes, both at night and in
the daytime, were increased from 2.0 L to 2.5 L. The patient
complained of daytime discomfort, however, and the daytime
dwells were reduced to 2.2 L each. The Kt/V remained at only
1.9/week while the CrCl was 51 L/week. The physician, again
concerned about failure to reach target levels, prescribed a
second daytime exchange to be done at mid-day during the
patient’s lunchtime break. The patient attempted this for a
while and clearance improved, but he then complained thatCASE PRESENTATION
his prescription had become too onerous. He requested that
Patient 1 he be switched from APD to hemodialysis therapy.
A 50-year-old man developed end-stage renal disease
(ESRD) secondary to IgA nephropathy. A teacher, he is mar- Patient 2
ried with teenage children and generally leads a busy life. He A 57-year-old man developed ESRD secondary to diabetic
attended patient education classes on the options for patients
nephropathy. Married with adult children, he worked as a saleswith ESRD and chose automated peritoneal dialysis (APD)
clerk in a department store. One year prior to initiation ofon the basis that it would be the least disruptive of his domestic
dialysis, he had chosen hemodialysis on the basis that it wouldand professional life. He weighed 80 kg. The initial APD pre-
be more convenient for his lifestyle. A fistula had been success-scription was five 2 L dwells nightly with a 2 L daytime dwell.
fully constructed and had matured well at the time of initiationA peritoneal equilibration test at 6 weeks showed that he
of dialysis. He weighed 68 kg.was a “low-average” transporter. Shortly afterwards, the first
He began a hemodialysis regimen of 4 hours three timesclearance measurements were made: the Kt/V was 2.1/week
weekly. A large-surface-area, high-flux hemodialyzer was used.(peritoneal Kt/V, 1.5; renal Kt/V, 0.6). Weekly creatinine clear-
His fistula had developed well and he quickly achieved a dia-ance (CrCl) was 65 L/week (peritoneal CrCl, 40 L/week; renal
lyzer blood flow in excess of 400 mL/min. Dialysate flow wasKt/V, 25 L/week). He did well on APD and continued to work
full-time. However, after 6 months his urine output decreased. set at 500 mL/min. The patient did reasonably well with interdi-
Repeat clearance measurements disclosed a weekly Kt/V of alytic weight gains of 2 kg during the week and 3 kg on week-
1.9 (peritoneal Kt/V, 1.5; renal Kt/V, 0.4), and a weekly CrCl ends. Serum calcium and phosphate levels generally were well
of 55 L/week (peritoneal CrCl, 40 L/week; renal CrCl, 15 controlled. Clearance measurements after 1 month showed that
L/week). A daytime exchange was added at 5:00 each evening the Kt/V was 1.5 per treatment and the urea reduction ratio
after the patient returned home from work. The Kt/V rose to (URR) was 0.72.
2.1/week and the CrCl to 61 L/week. The patient continued to The patient was aware that the DOQI target Kt/V for three
do well with no peritonitis or exit-site infection episodes. The times weekly hemodialysis is 1.2 per treatment and that the
target URR is 0.65. He said that he did not wish to spend any
more time on hemodialysis than was absolutely necessary, and
The Nephrology Forum is funded in part by grants from Amgen, he therefore requested a reduction in his dialysis time. His
Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo- physician expressed concern and argued that more dialysisrated; and Bristol-Myers Squibb Company.
would lead to better outcomes for the patient. The patient
Key words: Kt/V, urea reduction ratio, creatinine clearance, uremic insisted, however, and with each subsequent treatment, he
toxins, peritoneal dialysis, hemodialysis. “signed off” after 3.5 hours. A repeated Kt/V 1 month later
was 1.25 per treatment and the URR was 0.67. 2003 by the International Society of Nephrology
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DISCUSSION and other systemic diseases, including “unstable” coro-
nary artery disease. Therefore, the majority of a contem-Dr. Peter G. Blake (Chief of Nephrology, London
porary HD population would not have been eligible forHealth Sciences Centre; Professor of Medicine, University
this study. Patients were to receive the experimentalof Western Ontario, London, Ontario, Canada): Variants
protocol for a minimum of 24 weeks and for as long asof these two clinical scenarios arise frequently in the
48 weeks if possible. Follow-up was for as long as 3 years.practice of both hemodialysis (HD) and peritoneal dial-
Interim analysis at 22 weeks showed a significantly higherysis (PD). In each case, the physician acts to increase
morbidity rate in the two high BUN groups. Conse-dialytic clearances in the intuitive and deeply held belief
quently, the investigators discontinued these groups pre-that more dialysis leads to longer survival and generally
maturely. No significant difference in mortality rates wasimproved clinical outcomes. However, in each scenario,
noted, but medical withdrawal rates were greater in thesethe patient perceives that quality of life is impaired by
groups—45% and 62%, respectively—compared to 18%the dialysis regimen required to deliver the higher clear-
and 6%, respectively, in the two low BUN groups. Noances. The question that therefore arises is whether the
effect of time on medical withdrawal rates was seen. Theevidence supporting a beneficial effect of higher clear-
proportion of patients hospitalized at 1 year was alsoances is sufficient to justify the more onerous dialysis
significantly higher in the high BUN groups. With regardprescription that might be involved.
to this end point, the study discerned a trend towardI will argue here that the medical evidence supporting
an association between shorter dialysis time and morethe delivery of higher clearances in both HD and PD
hospitalization, with a P value of 0.06. In accordancehas been much weaker than is generally appreciated.
with convention, however, this trend was not reportedDespite this, a plethora of clinical practice guidelines
as being statistically significant [5]. It was of note that,have advocated particular clearance targets, and the ne-
although the high BUN groups terminated the studyphrology community widely believes that these targets
early, these patients continued to do poorly even afterare justified and, if anything, should be set at an even
they had resumed more standard dialysis schedules. Athigher level [1–4]. However, two recent randomized con-
a subsequent analysis one year later, a higher mortality
trol trials have upset conventional thinking in this area
risk was noted in the patients randomized to the high
and have raised important questions about the contem- BUN groups, with the risk approaching statistical sig-
porary practice of dialysis. nificance (relative risk 2.66, P  0.10).
What is not widely recognized, however, is the doseHemodialysis (HD)
of HD that the NCDS patients were receiving when
The roots of the dialysis community’s belief in the measured by today’s yardsticks—the Kt/V and the urea
importance of small solute clearance as a critical pre- reduction ratio (URR) [5]. As Table 1 shows, the two
dictor of patient outcome lie in the National Cooperative low BUN groups received, on average, a Kt/V of 0.85
Dialysis Study (NCDS), carried out between 1978 and per treatment corresponding to a URR of 0.57. The two
1980, and published in 1981 [5]. It is helpful for us to high BUN groups received, on average, a Kt/V of only
review this seminal study from a contemporary perspec- 0.45 per treatment with a URR of 0.30. The latter dose,
tive. The NCDS involved 151 patients from eight centers in particular, represents a level of HD that would never
who were randomized in 2  2 fashion to one of four be administered in normal clinical practice, either then
groups. The study looked at the influence of both dialysis or now. It thus might be suggested that the NCDS study
and blood urea nitrogen (BUN) concentration on patient was bound to have a positive result. Given that the low
outcome. Group 1 was dialyzed for 4.0 to 4.5 hours per clearance groups received so little dialysis, it was hardly
treatment to achieve a time-averaged BUN of 50 mg/dL surprising that their outcomes were so poor. I do not
(18 mmol/L). Group 2 also was dialyzed for 4.0 to 4.5 mean to be unduly critical of this innovative and influen-
hours but to a time-averaged BUN of 100 mg/dL (36 tial study, but it would be fair to say that it was not a very
mmol/L). Groups 3 and 4 were dialyzed for 3.0 to 3.5 exacting test of the importance of dialysis dose within
hours each to achieve a time-averaged BUN concentra- the current, normally prescribed clinical range.
tion of 50 mg/dL (18 mmol/L) and of 100 mg/dL (36 Notwithstanding this criticism, the NCDS firmly estab-
mmol/L), respectively (Table 1). To achieve the desired lished urea kinetics as the best measure of dialysis dose.
BUN levels, the dialyzer size, blood flows, dialysate flow It did not directly test clearance as a predictor of out-
rates, and direction were manipulated. come, but the subsequent retrospective analysis of the
The primary end point of the NCDS study was with- NCDS data base by Gotch and Sargeant [6] introduced
drawal due to death or for medical reasons, either related Kt/V to nephrology and appeared to make dialysis a
or unrelated to uremia. An additional primary end point more scientific practice. The NCDS therefore did not
was time to first hospitalization. This study excluded actually validate Kt/V as a measure of dialysis dose.
Randomization, as already pointed out, was determinedpatients over 70 years old and also those with diabetes
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Table 1. NCDS dataa
Target Achieved Midweek Medical
Time TAC BUNb TAC BUNb URR Kt/V predialysis withdrawal rate Non-hospitalized
Group hours mg/dL mg/dL (SEM) (—)c (—)b mg/dL (SEM) at 1 year (%) at 1 year (%)
I 4.290.03 50 51.31.1 0.57 0.85 71.21.4 18 86
II 4.300.03 100 87.71.4 0.35 0.47 104.91.7 45 46
III 3.190.03 50 54.11.1 0.55 0.80 73.11.4 6 69
IV 3.140.03 100 89.61.2 0.30 0.45 109.11.5 62 31
a Adapted from [5]. For medical withdrawal rates, P  0.0001 for effect of TAC urea; P  0.05 for effect of time; for hospitalization: P  0.0001 for effect of
TAC urea; P  0.06 for effect of time
b To convert blood urea nitrogen (BUN) to mmol/L, divide by 2.8; Kt/V approximations assume an nPNA of 1.0 g/kg/day (which was the mean nPNA achieved
in NCDS). For nPNA range of 0.6 to 1.2, the estimated Kt/V range is as follows: for groups I and III, Kt/V range is 0.4 to 1.05; for groups II and IV, Kt/V range is
0.2 to 0.6
c URR approximations assume ultrafiltration and urea generation rate of 0
by BUN level and not by clearance. It is ironic that Against this background, the recently completed HEMO
study asked whether still higher clearances would pro-judging the adequacy of dialysis by the BUN is now
considered to be a “cardinal sin,” in that a low urea duce even better outcomes. Randomization in this im-
portant 2  2 study was by Kt/V as well as by dialyzervalue fails to distinguish the well-dialyzed patient from
the malnourished one. I should further point out that in flux. In essence, the dialysis doses compared were a sin-
gle-pool Kt/V of 1.6, which corresponds to a URR ofthe two decades since the completion of the NCDS,
no randomized controlled trial has validated Kt/V as a 0.75, and a single-pool Kt/V of 1.2, which corresponds
to a URR of 0.65 [10].predictor of important clinical outcomes. Multiple obser-
vational studies have shown that higher levels of Kt/V
Peritoneal dialysis (PD)and URR are associated with improved survival but, as
every student of epidemiology knows, association is not Before considering the results of the HEMO study, I
will turn my attention to PD, a topic admirably reviewedcausation [7–9]. The association of high Kt/V with the
good outcomes in these studies might be a confounded by Oreopoulos [11] in a previous Nephrology Forum.
Once PD became established on a large scale in theone. Hemodialysis units and physicians who prescribe
high Kt/V might be good units or good physicians in 1980s, it was inevitable that the urea kinetic model would
be applied to it. Teehan et al [12], in an important paperother ways, in that they might manage other aspects or
complications of the uremic syndrome well. This possibil- published in 1985, first measured dialytic dose in continu-
ous ambulatory PD (CAPD) and soon Kt/V was beingity, rather than the increased Kt/V, might explain some
or all of the better outcomes. Similarly, patients who are tested as a predictor of outcome. It quickly became ap-
parent that the effect of clearance delivered continu-compliant and who are willing to undergo dialysis for
longer periods, or who accept and can achieve the higher ously, as occurs with CAPD or with a normal kidney,
was quite different from that of clearance delivered inblood flows, also might have baseline characteristics that
contribute to their superior outcomes. three short but intense HD sessions weekly. It became
evident that a Kt/V of 2.0 per week in PD had the sameDespite this lack of high-quality proof for the validity
of Kt/V as an indicator of dialysis adequacy, the nephrol- effect on BUN control as a weekly Kt/V of 3.6 delivered
as three HD treatments [13]. However, controversy en-ogy community has accepted the model enthusiastically.
On the basis of retrospective registry-type data, targets sued over the explanation for this finding [13, 14].
The first outcome studies looking for associations be-have been raised from the original Kt/V of 0.9 to 1.0 per
treatment suggested by Gotch and Sargent to the more tween clearances on PD and clinical end points showed
varied results [15, 16]. One of our early studies showedrecent Dialysis Outcomes Quality Initiative (DOQI) tar-
get value of 1.2, which corresponds to a URR of 0.65 no adverse effect on survival for Kt/V until the level
dropped below 1.5 per week [16]. Other investigators[2, 7]. Many have advocated raising the targets further,
and the view that “more is better” is widespread. The reported a more impressive effect [15]. Researchers soon
recognized that much of the variation in clearances inattraction of urea kinetics to nephrologists is obvious.
Here is a measure of dialysis dose (Kt/V) that is nephrol- PD was related to residual renal function, which had
been reported to be better preserved on PD than on HDogy-specific, generally only understood by nephrologists,
and that apparently leads to dialysis patients living [16, 17]. The CANUSA study [18], published in 1996,
appeared at first to establish conclusively the importancelonger. This measure seemingly makes the practice of
dialysis more scientific. It is not surprising that many of clearances in PD. This multicenter study followed
more than 600 incident CAPD patients and showed ain the nephrology community adopted these notions so
enthusiastically. significant association of both Kt/V and CrCl with patient
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Table 2. Mean values for total and peritoneal creatinine clearancesurvival. Thus, for every extra 0.1 Kt/V per week, the
(CrCl) and Kt/V in ADEMEX studya
relative risk of dying dropped by 6%. Similarly, for every
Standard High-clearanceextra 5 L of CrCl per week, the relative risk of dying
CAPD CAPDdropped by 7%. Similar results from Maiorca et al [19]
Peritoneal CrCl L/week 46 57supported the CANUSA findings, and these studies were
Peritoneal Kt/V V/week 1.62 2.13
the basis of the landmark 1997 DOQI guidelines, which Total CrCl L/week 53 63
Total Kt/V per week 1.80 2.27advocated a target Kt/V of 2.0 per week and a target
CrCl of 60 L per week for CAPD [1]. Higher levels were CAPD is continuous ambulatory peritoneal dialysis.
a Adapted from [29]recommended for APD on the basis that it was a more
intermittent modality. However, CANUSA was a pro-
spective cohort study and not a randomized controlled
trial [20]. Just like the HD studies supporting more Kt/V, resulted. Harty et al [27] completed a randomized con-
it could only show association and not causation. More trolled trial in 68 patients and found no outcome differ-
important, over 90% of the CANUSA patients received ence, but this study was too small and too short and thus
the standard 4  2 L CAPD prescription, so changes too underpowered to detect an effect. More recently,
in clearance were predominantly due to decreases in Mak et al [28] in Hong Kong randomized 82 prevalent
residual renal function [20]. When peritoneal clearance CAPD patients to 3 2 L compared to 4 2 L. Follow-
was analyzed separately, no independent effect was de- up was for a minimum of 12 months, and no survival
tected on survival or any other outcome [21]. Of course, difference was noted between the two groups. Again, this
it was not possible to meaningfully examine the influence study was significantly underpowered to detect an effect.
of peritoneal clearance in a patient cohort in which pre-
In 1998, however, a large and well-powered, multicenter,
scriptions were so uniform [22].
randomized, controlled, industry-sponsored study was
In the late 1990s, a variety of data bases were examined
initiated in Mexico to address this issue. First results
to look at the influence of clearance on outcome in PD
from the ADEMEX trial were reported in 2001 andpatients. Diaz-Buxo et al [23] and Rocco et al [24] showed
published in 2002 [29].the same pronounced effect that had been demonstrated
The ADEMEX study. The ADEMEX study random-in CANUSA. In each case, the effect was again totally
ized 960 incident and prevalent CAPD patients at 24attributable to residual renal function, and no indepen-
centers in Mexico. A minimum of 2 years follow-up wasdent effect of peritoneal clearance was apparent. The
planned. The control group received the standard 4 Rocco study disclosed significant variation in peritoneal
2 L daily CAPD regimen; the intervention group’s pre-clearance, which reflected the marked changes in PD
scription was altered to achieve a peritoneal CrCl of 60 Lprescription that were occurring in response to clinical
per week. This was done by increasing dwell volumes topractice guidelines by the late 1990s [24]. Despite the wide
2.5 or 3.0 L and by adding a fifth exchange delivered viarange of peritoneal clearances available for analysis, no
a night exchange device; APD was not used. The primaryeffect of PD clearance was seen, and this led to further
end point was patient survival, and secondary end pointsquestioning of the importance of higher peritoneal clear-
included technique failure, hospitalization, nutritionalance in the dose range commonly used.
measurements, and infection rates. Given the nature ofBoth Bhaskaran et al [25] in Toronto and Szeto et al
the intervention, it was, of course, not a blinded study.[26] in Hong Kong tried to approach this issue by looking
The mean age of the patients was 49 years, mean weightat anuric patients. The Toronto group retrospectively
was 68 kg, 58% were male, and 42% were diabetic.studied 122 anuric PD patients and showed an almost
Randomization in ADEMEX was very effective with nosignificant survival advantage (P  0.10) in patients who
baseline differences between the two groups. In particu-had a peritoneal Kt/V greater than 1.85/week [25]. Szeto
lar, they had similar residual renal function, body weight,et al prospectively followed 140 anuric CAPD patients
co-morbidity, and peritoneal clearances at enrollment.and were able to show, using multiple regression analysis,
Over the course of the study, the control group receivedan independent effect of peritoneal clearance on mortal-
on average a peritoneal CrCl of 46 L per week and aity with relative risk reductions similar to those seen in
peritoneal Kt/V of 1.62 per week. The treatment groupCANUSA. However, neither of these studies was ran-
had values of approximately 56 L and 2.13 Kt/V perdomized, and the possibility that healthier patients were
week, respectively (Table 2) [29].given more aggressive prescriptions with consequent
The study showed no significant difference in primaryconfounding of results cannot be excluded.
or secondary outcomes between the two groups. In par-Clearly, a prospective randomized controlled trial was
ticular, the relative risk of death in the intervention grouprequired to address this issue. Early efforts had not been
was 1.00. A variety of subgroups were examined, in-very successful [22]. Gotch attempted such a study in the
early 1990s, but recruitment was slow and no publication cluding those with and without diabetes, those with and
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without residual renal function, and those above and scription and adequacy. This large and ambitious multicen-
ter randomized controlled trial asked two clinically rele-below median body size. Again, no differences were ap-
parent. Technique failure rates did not differ between vant questions about the relationship between HD
prescription and patient outcome. Just as in ADEMEX,the two groups either. Distribution of causes was not
quite the same, however, with technique failure due to the answers were somewhat surprising [31].
The HEMO study was sponsored by the National In-uremia or hyperkalemia being significantly more com-
mon in the control group. However, in interpreting this stitutes of Health and carried out in 15 centers over a
6.5-year period. Patients were randomized in a 2  2finding, one needs to recognize that this was an open-
label study, and physicians might have been more likely fashion on the basis of clearance and flux. The standard
clearance group was targeted to achieve an equilibratedto attribute technique failure in the control group to
uremia or hyperkalemia. Kt/V (eKt/V) of 1.05, equivalent to a conventional single-
pool Kt/V of 1.25 and a URR of 0.65. The high clearanceA number of concerns have, nevertheless, been ex-
pressed about ADEMEX [30]. One is whether results group was targeted to achieve an eKt/V of 1.45, corre-
sponding to a single-pool Kt/V of 1.65 and URR of 0.75.from a Mexican PD population can be extrapolated to
patients in wealthier countries. Certainly, the ADEMEX With regard to flux, the patients were randomized to
low-flux dialyzers as defined by a 2-microglobulin (2m)patients are younger, weigh less, and have lower serum
albumin levels than do their U.S. counterparts. However, clearance less than 10 mL/min, or to high-flux dialyzers
with a 2m clearance greater than 20 mL/min. Patientsthe rates of diabetes, cardiovascular morbidity and mor-
tality, and overall survival in ADEMEX are very similar had to be between 18 and 80 years of age and undergoing
HD for more than 3 months. They had to be able toto those in western PD populations. This, as well as
the consistency of the ADEMEX findings on peritoneal achieve the high clearance targets in a 4.5-hour period,
so larger patients were effectively excluded. Substantialclearance with those from recent major North American
studies, including CANUSA, greatly decreases concerns residual renal function also was an exclusion criterion,
as was severe congestive heart failure or unstable angina.about the external validity of the study [18, 23, 24].
The question of prescription compliance in the high- The primary outcome was mortality. Secondary out-
comes included hospitalization for cardiovascular dis-clearance group also has been raised. Biochemical results
from ADEMEX suggest that the bulk of extra exchanges ease or infectious disease, all nonaccess hospitalization,
and persistent declines in serum albumin. The power cal-were done and, in any case, noncompliance will always
be a potential problem with the use of high clearance culations required 900 patients throughout the study,
so the investigation had a “recruit to replace” strategy.PD prescriptions in “real life” clinical practice.
The inclusion of prevalent, as well as incident, CAPD Altogether, 1846 patients were randomized. This gave
the study a greater than 80% power to detect a 25%patients in ADEMEX has been questioned [30]. Ideally,
a study should comprise incident patients only to avoid reduction in mortality. The mean age of the enrolled
patients was 58 years, mean weight was 69 kg, and 56%a population skewed toward those who are healthier.
Conversely, however, prevalent patients are much more were female. These criteria reflected the requirement
that patients be capable of achieving the high-clearancelikely to be anuric, and it is in the anuric population
particularly that one might most expect to see the benefit target. Almost 63% of the patients were black, 45% were
diabetic, and 80% had cardiovascular disease. Patientsof high clearance PD regimens. If prevalent and predom-
inantly anuric patients had not been well represented in had been on dialysis for a mean of 3.7 years prior to the
study. Randomization was successful, with no baselinethe ADEMEX study, the results likely would have been
criticized for just that reason. There was no beneficial differences between the groups.
The patient groups were well separated over the studytrend in ADEMEX for patients either with or without
urine output. duration in terms of clearance and flux. The achieved
single-pool Kt/Vs in the two groups were 1.32 and 1.71,In summary, ADEMEX is a well-conducted, random-
ized controlled trial. It is perhaps the best study of its corresponding to the URR values of 0.66 and 0.75, re-
spectively. Values for eKt/V were 1.16 and 1.53 in thekind to date in the dialysis literature. It has no apparent
major weaknesses. It was powered to detect a 20% reduc- two groups. These differences were partly due to, on
average, an extra 30 minutes of dialysis in the high Kt/Vtion in the relative risk of death, and it is possible that
a smaller effect might have been missed. The absence group and partly due to higher dialyzer clearance (Table
3). The study showed the expected impacts of age, race,of even a minimal trend in this direction will reassure
most observers that this is unlikely to be the case [29]. gender, diabetes, and serum albumin level on survival.
However, no difference was discerned with regard to theThe HEMO study. The impact of ADEMEX on PD
prescription and on nephrologists’ views about adequacy effects of high clearance or high flux on the primary
outcome. The relative risk of mortality for the high clear-of dialysis might have provided an interesting preview
of the effect that the HEMO study will have on HD pre- ance group was an insignificant 0.96 (confidence limits
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Table 3. Mean values for hemodialysis (HD) prescription dialysis patients. Neither study has any apparent serious
parameters in standard and high-clearance groups in the
flaw. In each case, the design was good and the questionHEMO studya
asked highly relevant to contemporary clinical practice.
Standard High Both have sufficient statistical power to detect a mortal-clearance clearance
ity reduction in the range of 20% to 25%. Neither can
eKt/Vb 1.16 1.53
exclude completely a smaller reduction. However, theSpKt/V 1.32 1.71
URR .66 .75 absence of even a hint of such a trend in ADEMEX
Dialysis time minutes 190 219 makes it unlikely that any clinically important effect was
Dialyzer blood flow mL/min 311 375
missed by that study. In the HEMO study, the relativeDialyzer urea clearance mL/min 218 251
risk in the high clearance group tended to be below 1.0a Adapted from [31]
b Abbreviations are: eKt/V, equilibrated Kt/V; SpKt/V, single-port Kt/V; URR, for the primary outcome and also for most of the second-
urea reduction ratio ary ones. But the study never came close to achieving
statistical significance, and it would be presumptuous of
us to overinterpret these findings. One might speculate,
however, that the appearance in the same year of these0.84 to 1.10, P  0.53) and for the high flux group was
two relatively similar studies, one for each modality,0.92 (0.81 to 1.05, P  0.23).
will be viewed in the future as a turning point in ourSimilarly, no differences appeared for secondary out-
understanding of the adequacy of dialysis.comes. A number of subgroup analyses, defined a priori,
were performed looking at age, gender, diabetes, race, Is dialysis dose still important?
co-morbidity, years on dialysis, and serum albumin level.
Before addressing further the relationship betweenA significant effect of higher clearance was noted in
dialysis dose and outcome, I would like to comment onfemales (but not in males) with a relative risk for mortal-
residual renal function. This was an issue only in theity of 0.81 (0.67 to 0.95, P  0.02). Somewhat more
ADEMEX study. In the HEMO study, patients wereimpressively, a significant benefit for high flux was found
excluded if the residual renal urea clearance exceeded
in patients who had undergone dialysis for more than
a very modest 1.5 mL/min [31]. In ADEMEX, however,
the mean time of 3.7 years. Here, the relative risk was almost one-half the patients had significant residual func-
0.68 (0.53 to 0.86, P  0.001). The real significance of tion and, just as was shown by the CANUSA study and
these subgroup effects is unclear, and one has to take other publications, a strong and apparently linear associ-
into account that multiple such comparisons were made, ation existed between residual function and patient sur-
leaving open the possibility that positive findings might vival [18, 29]. This relationship between residual clear-
be found by chance. The significant reduction in mortal- ance and outcome has been less well examined in HD,
ity identified for females in the high-dose group was but it is plausible, and indeed likely, that it is present
accompanied by a trend in the opposite direction for for that modality also [32].
males, with a relative risk of 1.16, although this number In contrast to this clear-cut relationship, the dose-
did not reach statistical significance. Is all this biologically response curve for dialytic clearance is far from clear
plausible? Could the difference perhaps represent a for either modality. Obviously, zero dialysis is associated
weight rather than a gender effect? These questions re- with uniformly poor outcomes, and even a modest
main to be answered. The association of high-flux HD amount prolongs life. However, ADEMEX and HEMO
with lower mortality in long-term HD patients is perhaps suggest that in the range of common clinical practice, the
more plausible in that large-molecule toxicity might take relationship between clearance and outcome has become
many years to become apparent. The model for this is, “flat.” From the NCDS, we know that in three-times-
of course, dialysis amyloidosis. weekly HD, a single-pool Kt/V of 0.85 is superior to one
Although the HEMO study might have yielded disap- of 0.45 per treatment [5, 7]. Somewhere between 0.85
pointing results in terms of expectations in the dialysis and the 1.32 given to the HEMO control group, the dose-
community, it is a methodologically sound study and response curve begins to flatten out. Registry data have
represents a magnificent effort on the part of the investi- suggested that this flattening occurs at a Kt/V of approxi-
gators, carried out over a sustained period, to address mately 1.2 [7, 8], although some recent studies suggest
key clinical questions in the contemporary practice of HD. that it might occur at a higher level [33]. Registry data
ADEMEX and HEMO. What common conclusions are full of potential confounders, however, and do not
can we draw from these two large, well-constructed, ran- provide the strength of evidence that a randomized con-
domized, controlled trials? First, it is worth emphasizing trolled trial does. Notwithstanding this, a reasonable as-
that both these studies are major contributions to the sumption is that the dose of dialysis delivered to the
dialysis literature. Indeed, they represent two of the control group in the HEMO study is at, or safely above,
the theoretical point where the curve flattens out. Asthree largest randomized controlled trials ever done in
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such, the present DOQI guidelines for HD appear ap- hours, on average, for the low-dose group [31]. By most
propriate [2]. standards, both of these are “short-time” HD prescrip-
For PD, the issue is more problematic. Registry-type tions. The findings of practitioners of longer duration or
data bases are relatively smaller for this modality but more frequent HD such as Charra et al [36] in France,
consistently do not show any association between peri- Pierratos [37] in Toronto, and Lindsay et al [38] at this
toneal clearance and survival [23, 24]. The levels of center are relevant in this regard. The benefits they de-
peritoneal clearance delivered to the control group in scribe in terms of volume and blood pressure control
ADEMEX—a Kt/V of 1.64 and a CrCl of 46 L/week— suggest that time and frequency are valid yardsticks by
did not put the patients at a disadvantage relative to the which to measure dialysis, and that this has not been
high clearance group, so it might be safe to assume that sufficiently taken into account in the urea kinetic model.
the break point is at or below these levels [29]. A recent, Another possibility is that the urea kinetic model is
as-yet-unpublished randomized controlled trial from deficient in that it inappropriately normalizes to body
Hong Kong suggests that patients receiving a total Kt/V size. Lowrie et al [39] has long argued that urea clearance
1.7 per week indeed might have poorer outcomes [34]. (Kt) without any normalization is a better, more linear
On the basis of these findings, the peritoneal Kt/V proba- predictor of patient survival in large HD data bases.
bly should be kept at or above 1.7 and the peritoneal Thus, the flattening out of the dose-response curve for
CrCl at or above 45 to 50 L/week. In both modalities, single-pool Kt/V values above 1.2 seen in a number of
these targets can be achieved in most patients without U.S. data bases can be eliminated by substituting an
excessively onerous prescriptions. We therefore should uncorrected Kt for Kt/V. The HEMO study did not ran-
be reluctant to engage in a “how low can we go?” exercise domize by Kt and does not allow us to assess this issue
by experimenting with still lower clearance levels. This directly. However, the high and low Kt/V groups did not
is one of the dangers that dialysis patients could face if differ at baseline in body weight and therefore did not
the results of these trials are interpreted as meaning that likely differ in V. The Kt thus would be expected to be
clearances are now unimportant. approximately 30% higher in the high clearance group,
Why are the effects of residual renal clearance so dif- just as Kt/V was. The lack of an outcome difference
ferent from those of dialytic clearance? This should not suggests that higher Kt within this commonly prescribed
surprise us so much. Residual renal function is associated dose range is not a more effective predictor than is a
with much more than small solute clearance. Relatively higher Kt/V. Only the borderline positive findings in
substantial residual renal function also gives the patient females, who typically weigh less, raise the issue that at
better volume control, better large-molecule clearance, a higher Kt a benefit might have been apparent [31].
and better endocrine and metabolic function. In many
The HEMO investigators will no doubt look at this issue
cases, it might simply reflect a generally healthier patient.
using their data base.
Is the yardstick wrong?
Why does clearance not have a greater effect?
An alternate interpretation of these studies is that we
Broadly speaking, two possible explanations accountare using the wrong yardstick to measure dialysis. Urea
for the unimpressive effects of higher clearance in theis not the definitive uremic toxin and might not be a
ADEMEX and HEMO studies. One is that the differ-good surrogate for the toxins that matter. The ADEMEX
ences in clearance between the groups in each studyresults suggest that creatinine is no better, and there is
were too small, reflecting not so much the deficienciesnot much support from HEMO for the notion that mid-
of the studies but rather the limitation of our presentdle molecules are crucial. Phosphate clearance has at-
paradigms for delivering dialysis. In other words, thetracted attention recently. A solute that diffuses poorly
increases in clearance that can be achieved with threeacross cell membranes, phosphate has no less than four
times weekly HD and contemporary PD might be insuf-phases of removal during HD. The toxicity and clearance
ficient to alter outcome. It is certainly true that the effi-kinetics of solutes such as phosphate, and also of putative
ciency of three-times-weekly HD does not increase inprotein-bound toxins, might be poorly reflected in the
proportion to the Kt/V. Thus, the apparent 30% greaterurea kinetic model and might, for example, be minimally
Kt/V in the high-dose group in the HEMO study trans-influenced by short duration high-flux HD [35].
lated into a difference of only about one-half as muchSalt and water might be the major uremic “toxins”
in so-called “effective clearance.” This small differencethat also have been neglected in the urea kinetic model.
again raises the argument for more frequent and longerLonger duration HD would be expected to show benefit
HD regimens. Here inefficiencies are much less, so eachif this were the case. The absence of a dialysis dose effect
unit of Kt/V will achieve greater solute removal. Longin the HEMO study does not make such an effect less
nocturnal HD, in particular, has the scope to achievelikely, given that the high-dose group received only, on
average, 3.5 hours with each treatment compared to 3.0 markedly higher true clearances and might show a more
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impressive effect on patient outcomes than the sort of Small studies and sporadic reports suggest large im-
provements in blood pressure control and in quality ofhigh-dose HD used in the HEMO study.
The other possibility is that increases in clearance life with daily HD regimens [37, 38]. These promising
results should be evaluated with the rigorous methodol-alone, no matter how large, might have limited potential
for improving outcome. We know of no plausible mecha- ogy of randomized control trials.
Research should focus on cardiovascular disease espe-nism by which tighter control of uremia would improve
patient survival in ESRD. Once a modest amount of cially. Probably the predialysis period is the best time to
intervene, but that is often not feasible for nephrologists.dialysis removes the risk of dying from hyperkalemia,
uncontrolled acidosis, fluid overload, uremic encepha- Particular attention should be given to the process of
inflammation, ubiquitous in chronic renal failure andlopathy, or severe malnutrition, it is not clear how more-
intense dialysis might prolong life further. More residual ESRD patients and largely unexplained [41]. Under-
standing and treating this cardiovascular risk factor morerenal function clearly does, but this likely works by many
mechanisms in addition to small-solute clearance. effectively are very important.
Finally, I would like to make a point about randomizedThe reality is that cardiovascular disease is the biggest
cause by far of mortality and morbidity in patients with controlled trials. The last decade has seen a number of
these in nephrology. Many have yielded surprising re-ESRD [40]. Risk factors include hypertension, diabetes,
smoking, and hyperlipidemia. High C-reactive protein sults and upset existing notions of what is effective and
what is not in renal failure. Normalization of hemoglobinlevels, hyperphosphatemia, a high calcium-phosphate
product, anemia, and perhaps hyperhomocysteinemia in HD patients with cardiac disease [46], dietary protein
restriction in chronic renal failure [47], and now, highalso may contribute to cardiovascular disease [41–44]. The
extent to which any of these factors can be significantly clearance regimens in both PD and HD, as well as high-
flux HD, are all strategies that nephrologists have broadlymodified by increasing dialytic clearance within the con-
ventional range is debatable. Furthermore, the majority supported. Each has now come into question, however,
after facing the rigor of a randomized controlled trial.of ESRD patients already have a high load of cardiovas-
cular morbidity when dialysis is initiated [40, 43]. It is The results of these trials often are disappointing to
nephrologists and hard to accept because they upset pre-plausible that any potential benefits of greater clearance
are completely obscured by the overwhelming influence conceived notions about how things are. Their findings
again emphasize that registry-based studies cannot allowof cardiovascular disease on patient outcome. It might
always have been naı¨ve of us to believe that patients us to infer causation and are frequently confounded.
For all these reasons, randomized controlled trials arewith congestive heart failure or widespread vasculopathy
could have their outcomes substantially modified by in- crucial. They challenge our thinking and give us the
opportunity to redirect our specialty toward more prom-creases, modest or otherwise, in dialytic clearance.
ising strategies. Those who carry them out with great
The future patience and over many years deserve our gratitude.
A conclusion from all this information is not that moni-
QUESTIONS AND ANSWERStoring and modification of dialytic doses are unnecessary;
neither ADEMEX nor HEMO supports such a notion. Dr. John T. Harrington (Dean, Tufts University
School of Medicine, Boston, Massachusetts, USA): Peter,The present DOQI hemodialysis targets need not be
altered, although I would argue that we have little justi- both your comments and Patient 1 demonstrate the criti-
cal importance of residual renal function to the well-fication for pushing Kt/V values much above 1.3 per
treatment [2]. The PD targets do need to be reduced being of PD patients. My specific question is, how often
do patients leave PD because of total loss of renal func-somewhat, however [1, 3]. The existing targets often
require prescriptions that unduly compromise patients’ tion? Could you also comment on the issue of “lead time
bias,” that is, patients beginning dialysis 1, 2, 3, or morelifestyles and are not justified by the evidence. The prac-
tice of adding peritoneal and residual renal clearance months before they actually need to.
Dr. Blake: Undoubtedly, the loss of residual renaltogether is no longer tenable. There should be targets
for the former, and the latter should be treated as a function corresponds with the time—2 to 4 years after the
initiation of PD—when many patients suffer techniqueprecious bonus to be preserved as long as possible. The
peritoneal Kt/V target should be in the range of 1.7 per failure. Is that cause and effect? Sometimes it is, but
many times it is not. In most countries and most centers,week. It is doubtful whether CrCl adds anything to this.
With regard to dialysis prescribing, we are likely at the biggest single cause of technique failure in PD contin-
ues to be peritonitis [48]. Notwithstanding this, manythe limit of our options with three times weekly HD and
conventional PD. The question now is whether daily patients appear to develop problems when they lose their
residual renal function. Some have difficulties with vol-HD, either short or long, or continuous-flow PD [45]
can improve outcomes above conventional paradigms. ume overload and hypertension, and others appear to
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be generally less well. ADEMEX suggests that these pa- clearance guidelines, but rather treat the patient as an
individual, and I think that is what you were saying.tients do not generally improve when we give them higher
clearance PD regimens. Conversely, however, many pa- Dr. Oreopoulos: If I may go on to the HEMO study,
the dilemma we have now with the findings of the HEMOtients who are anuric continue for a long time on PD.
Oreopoulos’ group has reported on a series of 140 such study is that if you give more dialysis, you do not get
additional benefits. Still, Lindsay and others like Charrapatients without renal function who were successfully
maintained on PD [25]. So residual function is frequently and Pierratos show that if you give more dialysis, the
patients do better [36–38]. Do you think it is time perhapsa major contributor to good patient outcomes, but in
many patients it is not indispensable. for us to forget completely about Kt/V and move toward
time and frequency of dialysis? Should we establish idealThe issue of lead time bias is also important. There is
a great deal of interest recently in starting patients earlier dialysis based on time and frequency, as Dr. Scribner and
I recently recommended [49]?on dialysis. We should not take it for granted that this
strategy is beneficial. If you start patients a year earlier Dr. Blake: I am aware of the recent hypothesis that
you and Dr. Scribner have proposed [49]. I think thereon dialysis, you have to take this into account when
you compare them with patients who started at a more is a case to be made for your approach, but I think it is
too early to dismiss Kt/V altogether. I have tried to em-conventional time. A randomized trial on this subject is
required. My understanding is that one is underway in phasize here that there is no evidence that higher Kt/Vs
are better than so-called conventional Kt/Vs, but evi-Australia.
Your question also raises the issue of residual renal func- dence in both modalities indicates that there is a lower
limit of Kt/V below which we should not let our patientstion with PD compared to HD. A number of studies show
that residual function is better preserved in PD, and this fall. It is not justified to say that Kt/V should be dis-
missed. It would be very dangerous to our patients if weis generally accepted [17]. Evidence also suggests, how-
ever, that in the United States, patients initiating PD have ignored the issue of clearance altogether after these two
negative studies. However, I do agree that it is time tomore baseline residual function than do those initiating
HD. This difference might reflect the fact that PD pa- look at other yardsticks for measuring dialysis. A new
hypothesis is very welcome in that regard. If a new yard-tients are more likely to have started dialysis electively.
Dr. Dimitrios Oreopoulos (Toronto Hospital, To- stick is accepted, I think we should validate it in a clinical
trial more promptly than was the case for Kt/V.ronto, Ontario, Canada): I want to continue on the point
that John raised. You said that the ADEMEX study Dr. Peter Cordy (London Health Sciences Centre,
London, Canada): I have two questions. You said thatshowed that if patients receive more dialysis, they don’t
do better. Actually, the ADEMEX study showed that if the practice of adding peritoneal and residual renal clear-
ance together is no longer tenable. Do you mean that ifyou give more dialysis, patients don’t survive longer. In
my experience, when these patients become anuric, they a patient has a peritoneal clearance of 1.5 and a renal
clearance of 0.4, you would then ensure that the perito-are usually symptomatic, nauseated, vomiting, restless,
more anemic, and they have higher phosphorus levels. neal clearance be increased to greater than 1.7?
Dr. Blake: Yes, I do. In general, I think peritonealIn my experience, again, if you increase the dialysis dose
in a large number of these patients, they do better. My and residual renal clearance should be regarded as two
very distinct entities. ADEMEX tells us that the formerquestion is, would you modify your recommendation
that the Kt/V be 1.7 “as long as they are not symptom- cannot replace the latter, so adding them together is not
really justifiable. Truly, these are the proverbial “applesatic?” If they are symptomatic, I believe they should get
more dialysis. and oranges.” ADEMEX tells us that a peritoneal clear-
ance of 1.64 is as good as one of 2.12, but it does notDr. Blake: The ADEMEX study showed that not only
do patients not live longer with high clearance regimens, tell us that it is safe to go below 1.64. Obviously, in patients
with very substantial renal function, it is possible to man-but also they do not have fewer hospitalizations or better
nutrition. Furthermore, I understand that there eventu- age them initially on low-clearance dialysis regimens, so
I might modify my opinion if the patient had a residualally might be data showing that these patients do not
have any advantage in terms of quality of life. Notwith- renal Kt/V greater than 1.0 per week. Our clinical experi-
ence tells us that such patients tend to do well.standing this, every PD practitioner is aware of patients
who become symptomatically uremic and then improve Dr. Cordy: What you say follows from the ADEMEX
study. On the other hand, we know that renal clearancewith an increase in the dialysis dose. Accordingly, I would
agree that every patient has to be treated as an individual, is much better than peritoneal clearance, so one would
have to say that someone who has a Kt/V of, for example,and a trial of increasing the dialysis dose is reasonable
in a given case. However, in a population study, this 1.8 from peritoneal clearance probably is not as well off
as someone who is achieving some of that from residualstrategy generally does not seem to work. I would con-
clude, therefore, that we should not get too focused on renal function. That was really my point.
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Dr. Blake: Again, I agree with you. The patient with weigh a mean of 68 kg are reasonable. This is a concern
to a lot of nephrologists outside the United States, espe-a greater contribution from residual renal function will
tend to be better. My point, however, is that you can’t cially those who have long been uneasy with the short
dialysis times used in some U.S. centers. Many of usreplace the residual function, one for one or unit for
unit, with peritoneal clearance and hope to have the same wonder whether control of blood pressure and cardiovas-
cular outcomes might have been better in the HEMObeneficial effect on patient survival or other outcomes.
Dr. Cordy: You might have partially answered my study if the patients had received 4 to 5 hours instead
of 3 to 3.5 hours of treatment. I would therefore empha-other question. If more is not necessarily better, and a
certain amount, for example, a Kt/V of 1.8, is sufficient, size the fact that the control group in the HEMO study
got a Kt/V of 1.3 per treatment and that the DOQI guide-should we now revert to CAPD and “classic” CCPD as
opposed to automated therapy with at least one daily lines for HD adequacy still apply. I do not think the HEMO
study allows us to draw any conclusions about the impor-exchange?
Dr. Blake: I think much of the move to APD over tance of dialysis time. I will continue to argue that the
most important determinant of dialysis time should bethe past decade reflects patient choice. Physicians might
have been inclined to prescribe more APD for adequacy the patient’s need for adequate fluid removal and opti-
mal blood pressure control.reasons, but the patient perspective was that APD is as-
sociated with a better lifestyle. Accordingly, most patients, Dr. Jatin Kothari (King Edward Memorial Hospital,
Mumbai, India): You mentioned a minimum target forif given a choice, will not be willing to use standard CAPD
instead of APD. However, I think standard CAPD was peritoneal Kt/V of 1.7. The control group in ADEMEX
had a Kt/V of 1.62, and the group from Toronto showeddiscarded too precipitously in many centers. It is an ex-
cellent therapy for many patients. As we know from that if a patient has a Kt/V of less than 1.8, the outcome
is worse [25]. Should we have any minimum target valuethe Canadian registry, the survival results achieved with
CAPD are excellent [50]. for the Kt/V, or should we individualize treatment for
each patient? My second question is, do you think thatDr. Mukesh Khandelwal (Bombay Hospital, Mum-
bai, India): You described a patient on APD, and the more people should start with PD as first-line therapy,
unless contraindicated, since we know it preserves resid-ADEMEX study included patients on CAPD, so can we
extrapolate these results to APD patients? ual renal function for a longer duration than does HD?
Dr. Blake: In answer to your first question, I think aDr. Blake: Your question concerns whether the
ADEMEX results can be extrapolated to APD patients. peritoneal Kt/V of 1.7 is a reasonable cutoff. The Bhask-
aran study suggested a value of 1.85, but it was a retro-This is a concern. The ADEMEX study comprised only
CAPD patients, and the high-clearance group used night spective study with consequent potential biases, so the
randomized controlled trial would take precedence [25].exchange devices and larger dwell volumes but did not
use cyclers. Strictly speaking, the results therefore cannot I agree that more patients should use PD as an initial
therapy. There is convincing evidence that it preservesbe applied to APD. I would ask, however, whether APD
is so very different from CAPD. I do not think that any- residual renal function better than HD. More important,
there is evidence from the United States, Canada, andone is going to repeat the entire trial in APD patients.
I think this is the best evidence we are going to have, elsewhere that patient survival on PD is at least as
good—and perhaps better—than that on HD in the earlyand my view is that the same principles apply to both
modalities. I cannot prove this, but it seems a reasonable years of dialysis [50, 51].
Dr. Louise Moist (London Health Sciences Centre):supposition.
Dr. Rita Suri (London Health Sciences Centre): The My first question is related to the ADEMEX study. As
you pointed out, the overwhelming cause of death waspractice of high-efficiency, short-time hemodialysis, widely
implemented after the NCDS, appeared to dismiss the from cardiovascular disease and infection. But the more
concerning point for a nephrologist was that congestiveeffect of dialysis time, and many physicians attributed
the high mortality rates on dialysis in the 1980s in the heart failure was responsible for 13.4% of deaths in the
control and only 5.7% in the intervention subjects. Simi-United States to the fact that this practice was widely
followed. Do you think that the HEMO study now pro- larly, as you pointed out, uremia, hyperkalemia, and aci-
dosis contributed to 12.2% of deaths in the control andvides renewed justification for this practice and, given
what happened after the NCDS, what do you anticipate 5.1% in the intervention groups [29]. As nephrologists,
we are in the business of dialysis, and the deaths fromthe long-term outcomes will be?
Dr. Blake: Yes, I think this is a danger. It would be those causes—congestive heart failure, uremia, acidosis,
and hyperkalemia—are the ones that we try to preventa shame if the HEMO study were interpreted as meaning
that low Kt/Vs and short dialysis times are safe. Some from day to day. Do you think the more challenging
causes of death—coronary artery disease and infection,might interpret the HEMO study as indicating that dial-
ysis times averaging 3 hours in a group of patients who as you mentioned—will have to be dealt with earlier,
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such as in a chronic renal failure clinic, before we get to is certainly continuous, and that might be where its bene-
fit lies. The bad side about PD is that it is somewhat in-the dialysis unit? So my real question is, if we adopt a
low-dose dialysis prescription, do you think we will be efficient. You, Dr. Oreopoulos, and others have tried to
increase efficiency, but you are limited by how much fluidseeing more of the dialysis-related deaths, those that we
have been trying to prevent over the last several years? you can put in per unit time, what surface area exists,
and so on. All your modifications of trying to alter theDr. Blake: With regard to your first point, I do note
the higher rates of death attributed to congestive heart membrane permeability, frankly, just did not work. So
we are kind of stuck. Hemodialysis is actually extremelyfailure, uremia, hyperkalemia, and acidosis in the control
as compared to the intervention group in the ADEMEX efficient, but the problem is its discontinuity. When you
think about it, how we got into the paradigm of three-study. However, there was no overall difference in death
rates between the two groups, and one has to be mindful times-a-week HD and have stuck there for the last 25 or
30 years is not in any way based on human renal physiol-that this was an “open-label” study. I strongly suspect
that the “unblinded” physicians were more likely to attri- ogy. That regimen came as an unfortunate middle-of-
the-road compromise among three factors: what little webute death or technique failure to diagnoses such as ure-
mia and congestive heart failure when they occurred in knew about adequacy, what patients and nurses would
tolerate, and the economics. Usually these three werethe control group. This is not, in my view, a convincing
finding. We are left with the “hard” result showing no pulling in different directions. I think the issue now is
how we can change the current treatment paradigm. Thedifference in survival between the two groups.
With regard to your second point, I agree that cardio- beauty of HD is that we can decrease its discontinuity
and make it much more like a continuous therapy, withvascular disease needs to be tackled earlier—in the chronic
renal failure clinic or even before that. For many pa- quotidian overnight or “short-hours” daily therapy. The
HEMO study tells us that there is little or nothing to betients, end-stage renal failure occurs at a late phase in the
progression of the cardiovascular disease that ultimately gained by increasing the efficiency of a single treatment
to beyond that already established when it is used onlydetermines their life expectancy. Modification of risk
factors much earlier is surely the way to go forward here. three times per week. I do not think that is too surprising.
We now have to study what happens when we increaseDr. Moist: Do you think we should have population-
based dialysis dose targets as recommended by DOQI the frequency.
Dr. Harrington: Dr. Lindsay, what is the evidenceand the CSN, or should we develop individualized targets
based on gender, your data, patients’ lifestyles, clinical for the sermon you just gave us? Do you know that
quotidian overnight dialysis works?symptoms, and laboratory parameters?
Dr. Blake: In an ideal world, we might generate and Dr. Lindsay: I know that it works from our own pro-
spective, cohort-controlled study [38]. But I do agreeindividualize targets to each patient based on gender,
lifestyle, life expectancy, and other factors. In practice, that there has not been a randomized prospective study
on survival, and that enough evidence supports conduct-we need to simplify things a little, and I still think there
is a role for overall dialysis-dose targets. The important ing a randomized prospective study of quotidian HD
versus conventional HD.point is not to see these as something rigid and immuta-
ble, but rather as one of many parameters that are part Dr. Mohammed Alsunaid (King Faisal Specialist Hos-
pital and Research Centre, Riyadh, Saudi Arabia): Do youof the overall patient management plan.
Dr. Harrington: Are there long-term studies of 10- think that we should disregard weekly CrCl in assessing
the adequacy of dialysis, and look only for urea clear-to 20-year survivors in either HD or PD? Such studies
might provide clues as to how we can improve care for ance, Kt/V?
Dr. Blake: I am very sympathetic to this point of view.the rest of the population. They could also be rich sources
of data for functional genomics studies. I think we have made a mistake in PD by having far too
many targets. Let me summarize what we have at pres-Dr. Blake: There are some data on this in PD [52].
Long-term survivors are, of course, more likely to be pa- ent. We have Kt/V and CrCl targets. We have targets
for CAPD and APD with and without day dwells. Wetients who initiated dialysis at a younger age. Similarly,
less baseline co-morbidity is associated with better sur- also have targets for high and low transporters. So we
end up with about 12 different permutations. There isvival. Other factors associated with long-term survival
include female gender, Asian race, and smaller body simply no clinical evidence to support all this and it has
made PD too complex. There is a danger of putting offhabitus. I know of no evidence that any particular geno-
type predicts better survival, however. all but the most enthusiastic PD practitioners. My view
is that CrCl does not add anything above and beyondDr. Robert Lindsay (London Health Sciences Cen-
tre): The human kidney is unbelievably efficient; it works Kt/V. Studies that show CrCl to be a better predictor of
outcome merely reflect the fact that it gives higher weightcontinually whether native or transplanted. This is the
ideal for renal replacement therapy. Peritoneal dialysis to residual renal outcome. I would advocate that we have
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